Antisense Therapeutics (ANP) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialise novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy, multiple sclerosis and acromegaly.
ANP has three products including ATL1102 injection for multiple sclerosis, ATL1103 injection for growth & sight disorders, and ATL1102 inhaled for asthma.
| Rank | Company | # | |
|---|---|---|---|
| 969th | - | Antisense Therapeutics | $1.58m |
|
NEW ROLE: Anthony Filippis, | 02 Oct 2023 |
|
NEW ROLE: Gil Price, Consultant Medical Director, Non-Executive Director since 2021 | 11 Oct 2021 |
|
|
NEW ROLE: Alicia Mellors, Joint Company Secretary | 29 Mar 2021 |
|
NEW ROLE: Charmaine Gittleson, Non-Executive Chair | 29 Mar 2021 |
|
|
NEW ROLE: Nuket Desem, Director-Clinical & Regulatory Affairs | 24 Nov 2020 |
|
|
NEW ROLE: George Tachas, Director Drug Discovery and Patents | 24 Nov 2020 |
|
NEW ROLE: Graham Mitchell, Non-Executive Director | 03 Nov 2020 |
|
NEW ROLE: Gary Pace, Non-Executive Director | 03 Nov 2020 |
|
|
NEW ROLE: Robert Moses, Non-Executive Director, was Chair 2001-2021 | 03 Nov 2020 |
